Korro Bio Inc. reported third quarter 2025 financial results, with cash, cash equivalents, and marketable securities totaling $102.5 million as of September 30, 2025, down from $163.1 million at December 31, 2024. The company expects its cash position to fund operations into the second half of 2027. Collaboration revenue for the quarter was $1.1 million, compared to no collaboration revenue in the same period of 2024, due to income from Korro's collaboration with Novo Nordisk. Research and development expenses were $13.8 million, down from $16.0 million in the prior year period, mainly due to decreased KRRO-110 and pre-development candidate expenses. General and administrative expenses were $6.5 million, compared to $7.3 million in the third quarter of 2024, primarily reflecting lower professional services costs. Net loss for the quarter was $18.1 million, compared to $21.0 million in the same period last year. Business developments included the announcement that KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency patients, though not at projected levels, leading to a pivot to GalNAc delivery with a development candidate nomination expected in the first half of 2026. The company also nominated KRRO-121, a candidate for hyperammonemia, and announced the resignation of Chief Medical Officer Dr. Kemi Olugemo, effective November 12, 2025.